La Voz de Asturias has published a report highlighting NEUROSTECH’s activities, particularly the research and development of new medical devices for the treatment of neurological conditions. NEUROSTECH is dedicated to the development and production of medical devices to optimize the treatment of neurological diseases such as Alzheimer’s, Parkinson’s and ALS.
To better understand where this project comes from and all the potential it has to improve the quality of life of patients and their families, Gabriel Álvarez, Ph.D., CEO of NEUROSTECH, chemist and visible head of the research together with CSO Catuxa Prado, Ph.D., (biochemist) were interviewed.
Gabriel Álvarez describes the current scenario: “The development of this project will provide a new route for the administration of drugs for the treatment of neurological diseases, which is currently very complex due to the existence of a biological barrier (the blood-brain barrier), which prevents drugs administered by conventional means from reaching the Central Nervous System”. Thanks to the joint work of a doctor, a chemist and a biochemist and their combination of knowledge and skills in different areas such as basic and clinical neurosciences, biochemistry and pharmacology, the Neuroscience Foundation has created the spin off Neuroscience Innovative Technologies SL (NEUROSTECH) whose primary objective is the development of prototypes of an implantable device for the elimination of pathogens from the central nervous system. “Getting drug release into the central nervous system in a very controlled way is our main motivation”, explains Gabriel.
“Driving this technology forward and taking it to a level of development that can respond to an important unmet need at the present time” is the great challenge that occupies NEUROSTECH. In this way, treatments for certain neurological diseases will reach the right place to be effective and safe, since they do so in a controlled way. It is precisely this last point that sets them apart from other existing developments on the market. “No other technology acts directly on the Central Nervous System with an implantable device in the body that allows it to work 24 hours and with the certainty that the drug will not have direct contact with the organism, avoiding any safety problem”.
